Pharmaceutical dealmaking reaches $106 billion as large drugmakers pursue biotech acquisitions to refill pipelines and offset looming patent losses

Pharmaceutical mergers and acquisitions have reached about $106 billion in 2026 as major drugmakers buy or target biotech companies to rebuild product pipelines and prepare for upcoming patent expirations. Large-cap pharma companies are using acquisitions to secure late-stage assets, new platforms, and future revenue sources as pressure grows from loss of exclusivity on blockbuster medicines. Biotech valuations, financing conditions, and strategic demand for innovation are shaping the current wave of dealmaking. The activity reflects a broader industry push to balance risk, speed development, and gain access to differentiated therapies that can support long-term growth. The surge matters because consolidation can redirect capital, determine which experimental medicines advance fastest, and influence competition across therapeutic areas.